Skip to Main Content

For further information, see CMDT Part 36-09: Blastomycosis

Key Features

  • Most often in men infected during outdoor activities

  • Geographically limited to south central and midwestern US and Canada

Clinical Findings

  • Chronic pulmonary infection most common; may be asymptomatic

  • Cough, fever, dyspnea, chest pain; may resolve or progress, with purulent sputum, pleurisy, fever, chills, weight loss, prostration

  • With disseminated, lesions most frequently occur in skin, bones, urogenital system

  • Raised, verrucous cutaneous lesions commonly present in disseminated disease

  • Bone lesions often in ribs and vertebrae

  • Epididymitis, prostatitis, and other involvement of the male urogenital system

  • CNS involvement uncommon

  • In HIV-infected persons, disease may progress rapidly; dissemination common


  • Leukocytosis and anemia

  • Chest radiograph or CT scan: lobar consolidations or masses

  • Clinical specimen: organism is a 5–20 mcm thick-walled cell; may have single broad-based bud. Blastomyces grows readily on culture

  • Serum enzyme immunoassay based on the surface protein BAD-1

    • Has better sensitivity and specificity than urinary antigen test

    • Not yet commercially available

  • A urinary antigen test is available

    • Has considerable cross reactivity with other dimorphic fungi

    • May be useful in monitoring disease resolution or progression


  • Itraconazole, 200–400 mg orally once daily for at least 6–12 mo, for non–life-threatening, non-CNS disease; response rate of > 80%

  • Liposomal amphotericin B, 3–5 mg/kg/day intravenously, is given initially for severe disease, treatment failures, or CNS involvement

  • Monitor patients several years for relapse

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.